MedPath

Investigation of interindividual factors in nivolumab pharmacokinetics and adverse events in Japanese patients with non-small-cell lung cancer and renal cell cancer

Not Applicable
Recruiting
Conditions
on-small-cell lung cancer, renal cell cancer
Registration Number
JPRN-UMIN000041082
Lead Sponsor
Department of Hospital pharmacy Hamamatsu University School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
100
Inclusion Criteria

Not provided

Exclusion Criteria

Patients who are judged by physicians as inappropriate for study enrollment

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Serum nivolumab concentration just before dosing at 7th administration or later
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath